Dementia Associated With Alzheimer's Disease Pipeline, Emerging Drugs Approvals, Clinical Trials and Companies | DelveInsight

DelveInsight's, "Dementia Associated With Alzheimer's Disease Pipeline Insight" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Dementia Associated With Alzheimer's Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Dementia Associated With Alzheimer's Disease Research. Learn more about our innovative pipeline today! @ Dementia Associated With Alzheimer's Disease Pipeline Outlook- https://www.delveinsight.com/sample-request/dementia-associated-with-alzheimers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Dementia Associated With Alzheimer's Disease Pipeline Report
• In October 2024:- Karuna Therapeutics- This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD. The primary objective of the study is to evaluate the efficacy of KarXT compared with placebo in the treatment of subjects with psychosis associated with AD as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.
• In October 2024:- Intra-Cellular Therapies, Inc.- A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study of the Efficacy, Safety, and Tolerability of ITI-1284 in Patients With Agitation Associated With Alzheimer's Dementia. This is a multicenter, randomized, double-blind, placebo-controlled, flexible-dose study of the efficacy, safety, and tolerability of ITI-1284 in patients with agitation associated with Alzheimer's dementia.
• DelveInsight's Dementia Associated With Alzheimer's Disease pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Dementia Associated With Alzheimer's Disease treatment.
• The leading Dementia Associated With Alzheimer's Disease Companies such as BioVie, Karuna Therapeutics, Cassava Sciences, Inc., Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., and others.
• Promising Dementia Associated with Alzheimer's disease Therapies such as KarXT, ITI-1284, and others.

Stay informed about the cutting-edge advancements in Dementia Associated With Alzheimer's Disease treatments. Download for updates and be a part of the revolution in cancer care @ Dementia Associated With Alzheimer's Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/dementia-associated-with-alzheimers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dementia Associated With Alzheimer's Disease Emerging Drugs Profile
• NE3107: BioVie
NE3107 is an orally available small molecule with potential anti-inflammatory and insulin-sensitizing properties that can cross the blood-brain barrier. It was originally developed by NeurMedix and acquired by BioVie in April. The experimental molecule works by blocking the activation of two major regulators of inflammatory pathways: extracellular signal regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). NFκB is activated by amyloid beta and tau - two proteins that form toxic clumps that contribute to Alzheimer's - and by the pro-inflammatory molecules that it stimulates, leading to chronic inflammation. NE3107 was found to have no immunosuppressive effects and to block ERK- and NF-κB-induced inflammation without suppressing their functions involved in maintaining overall balance, such as insulin signaling and nerve cell growth and survival. Currently, the drug is in Phase III stage of development for the treatment of Alzheimer Disease.

• KarXT: Karuna Therapeutics
KarXT, a combination of xanomeline and trospium, is an investigational treatment developed by Karuna Therapeutics, primarily aimed at addressing psychosis associated with Alzheimer's disease (AD) and schizophrenia. KarXT functions as a muscarinic receptor agonist, specifically targeting the M1 and M4 muscarinic acetylcholine receptors. Xanomeline activates these receptors, which are crucial for cognitive processes such as learning and memory. Trospium, on the other hand, is included to mitigate peripheral side effects associated with xanomeline, such as nausea and vomiting, by preventing its action on muscarinic receptors outside the brain. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Dementia Associated With Alzheimer's Disease.

• Simufilam: Cassava Sciences
Simufilam (formerly known as PTI-125) is an investigational drug being developed by Cassava Sciences. It targets an altered form of filamin A (FLNA), a protein implicated in the disease's pathology. Unlike traditional Alzheimer's treatments that focus on clearing amyloid plaques, simufilam works by stabilizing FLNA, thereby potentially reducing neuroinflammation and cognitive decline associated with the disease. Currently, the drug is in the Phase III stage of development to treat Dementia Associated With Alzheimer's Disease.

• CT-1812: Cognition Therapeutics
Cognition Therapeutics isdeveloping CT1812, an oral, brain-penetrant, small molecule therapeutic, which has been shown to protect neurons and synapses by preventing the binding of toxic oligomers. CT1812 acts as a neuroprotective agent both by shielding neurons and synapses from oligomer binding and by preventing oligomers from attaching to synapses in the first place. CT1812 may help mitigate the neurotoxic effects, slowing cognitive decline and progression of Alzheimer's disease. Currently, the drug is in the Phase II stage of development to treat Alzheimer's-disease.

• CM383: KeyMed Biosciences
CM383 is an investigational drug being developed for the treatment of Alzheimer's disease. It is a small molecule designed to target the underlying mechanisms of the disease, specifically by modulating the immune response and reducing neuroinflammation, which are key factors in Alzheimer's pathology. CM383 works by targeting the immune system's response to amyloid-beta plaques, which are characteristic of Alzheimer's disease. It aims to enhance the brain's ability to clear these plaques and improve neuronal health. This approach is distinct from many traditional Alzheimer's treatments that primarily focus on amyloid plaque reduction or cholinergic modulation. Currently, the drug is in the Phase I stage of development to treat Alzheimer's-disease.

Learn more about Dementia Associated With Alzheimer's Disease Drugs opportunities in our groundbreaking Dementia Associated With Alzheimer's Disease Research and development projects @ Dementia Associated With Alzheimer's Disease Unmet Needs- https://www.delveinsight.com/sample-request/dementia-associated-with-alzheimers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dementia Associated With Alzheimer's Disease Companies
BioVie, Karuna Therapeutics, Cassava Sciences, Inc., Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., and others

Dementia Associated With Alzheimer's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Dementia Associated With Alzheimer's Disease Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Dementia Associated With Alzheimer's Disease treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Dementia Associated With Alzheimer's Disease Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/dementia-associated-with-alzheimers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Dementia Associated With Alzheimer's Disease Pipeline Report
• Coverage- Global
• Dementia Associated With Alzheimer's Disease Companies- BioVie, Karuna Therapeutics, Cassava Sciences, Inc., Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., and others.
• Dementia Associated with Alzheimer's disease Therapies- KarXT, ITI-1284, and others.
• Dementia Associated With Alzheimer's Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Dementia Associated With Alzheimer's Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Dementia Associated With Alzheimer's Disease Pipeline on our website @ Dementia Associated With Alzheimer's Disease Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/dementia-associated-with-alzheimers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Dementia Associated With Alzheimer's Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dementia Associated With Alzheimer's Disease- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. NE3107: BioVie
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CT-1812: Cognition Therapeutics
12. Early Stage Products (Phase I)
13. CM383: KeyMed Biosciences
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. Drug name: Company name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Dementia Associated With Alzheimer's Disease Key Companies
20. Dementia Associated With Alzheimer's Disease Key Products
21. Dementia Associated With Alzheimer's Disease- Unmet Needs
22. Dementia Associated With Alzheimer's Disease- Market Drivers and Barriers
23. Dementia Associated With Alzheimer's Disease- Future Perspectives and Conclusion
24. Dementia Associated With Alzheimer's Disease Analyst Views
25. Dementia Associated With Alzheimer's Disease Key Companies
26. Appendix

List of Top Selling Market Research Reports in 2025

Varicose Vein Treatment Devices Market - https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Vascular Access Devices Market - https://www.delveinsight.com/report-store/vascular-access-device-market
Indwelling Catheters Market - https://www.delveinsight.com/report-store/indwelling-catheters-market
Healthcare Competitive Benchmarking - https://www.delveinsight.com/consulting/competitive-benchmarking-services
Lymphoedema Market - https://www.delveinsight.com/report-store/lymphoedema-market
Pacemakers Market - https://www.delveinsight.com/report-store/pacemakers-market
Myeloproliferative Neoplasms Market - https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
Surgical Mask & Respirator Market - https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Nk Cell Therapy Market - https://www.delveinsight.com/report-store/nk-cell-therapy-market
Novel Drug Delivery Devices Market - https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Testicular Neoplasm Market - https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight
Phototherapies For Psoriasis Market - https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Skin Neoplasm Market - https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market
Microscopy Device Market - https://www.delveinsight.com/report-store/microscopy-device-market
Bone Growth Stimulator Market - https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Urea Cycle Disorders Market - https://www.delveinsight.com/report-store/urea-cycle-disorders-market
Antibody Drug Conjugate Market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Cardiac Implantable Electronic Devices Market - https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market
Dyspepsia Market - https://www.delveinsight.com/report-store/functional-dyspepsia-epidemiology-forecast-insight
Lactose Intolerance Market - https://www.delveinsight.com/report-store/lactose-intolerance-market
Medical Marijuana Market - https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Asperger Syndrome Market - https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
Catheter Stabilization Devices Market - https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

This release was published on openPR.